Yung Zip Chemical Ind. Co., Ltd. · TPEX:4102
Yung Zip Chemical Ind — Investors Relations Conference 2019
22 slides from Yung Zip Chemical Ind's conference presentation, Sep 26, 2019
Slide 1: Investors Relations Conference 2019
Stock Code：4102 Yung Zip Chemical Ind. Co., Ltd. Investors Relations Conference 2019 Sep. 26, 2019
Slide 2: Disclaimer
Disclaimer This material has been prepared by Yung Zip Chemical Ind. Co., Ltd. (“YZC”). • Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of YZC. Without limiting the foregoing, statements inc
Slide 3: Agenda
Agenda 1st • Company Introduction • Financial Performance 2nd Overview 3rd • Business Development 3
Slide 4: Agenda
Agenda 1st • Company Introduction • Financial Performance 2nd Overview 3rd • Business Development 4
Slide 5: Company Introduction: Philosophy
Company Introduction: Philosophy Established on June 8, 1978, Yung Zip Innovation Chemical Ind. Co., Ltd. adheres to the sustainable management philosophy of “innovation, effectiveness and service”, and abides by honesty, reliability and rigorous business ethics. Over decades of growth and experienc
Slide 6: Company Introduction- GMP History
Company Introduction- GMP History 2009 2017 2019 1990 2001 Passed Passed the Passed the On March Passed the inspection by third first 20, Yung third UK MHRA and certification inspection Zip is inspection by passed the by TFDA by the US listed on Japanese first inspection PIC/S FDA the stock PMDA by
Slide 7: Agenda
Agenda 1st • Company Introduction • Financial Performance 2nd Overview 3rd • Business Development 7
Slide 8: Statement of Comprehensive Income
Statement of Comprehensive Income Items 1H’19 1H’18 YoY (in NT$ thousand) (Reviewed) (Reviewed) Operating Revenue 214,289 149,392 43% Gross Profit 61,929 23,961 158% Gross Margin 29% 16% Operating Expenses 44,577 39,010 14% Operating (Loss) 17,352 (15,049) 215% Operating Margin 8% -10% Other Rev. (E
Slide 9: Increasing profits gradually and out of the red during 2019
Increasing profits gradually and out of the red during 2019 400,000 40.00% 350,000 35.00% 300,000 30.00% 250,000 25.00% 200,000 20.00% 150,000 15.00% 100,000 10.00% 50,000 5.00% 0 0.00% 2016 2017 2018 1H' 2019 -50,000 -5.00% -100,000 -10.00% Net Operating Revenue Post-tax profit or loss Gross Margin
Slide 10: Balance Sheet
Balance Sheet Items 2019/6/30 2018/6/30 2017/6/30 (in NT$ thousand) (Reviewed) (Reviewed) (Reviewed) Cash and Cash 39,501 6% 11,829 2% 24,749 5% Equivalents Accounts receivable 101,928 16% 78,147 13% 70,562 13% Inventories 133,697 20% 123,652 21% 78,147 14% Long-term Investments 128,059 19% 122,523
Slide 11: Cash Flow
Cash Flow 1H’19 1H’18 1H’17 (in NT$ thousand) (Reviewed) (Reviewed) (Reviewed) Cash and cash equivalents at beginning 40,159 29,673 44,024 of period Cash flows from 13,198 (9,385) (7,445) operating activities Cash flows from (13,035) (8,459) (11,830) investment activities Cash flows from (821) 0 0 f
Slide 12: Agenda
Agenda 1st • Company Introduction • Financial Performance 2nd Overview 3rd • Business Development 12
Slide 13: Jan.~Aug. Operating Revenue (2018 VS 2019)
Jan.~Aug. Operating Revenue (2018 VS 2019) Operating Revenue 300,000 250,000 200,000 150,000 100,000 50,000 0 01~08/’18 01~08/’19 (in NT$ thousand) 01~08/’18 01~08/’19 YoY Operating Revenue 206,793 283,910 37% 13
Slide 14: Sales Distribution
Sales Distribution (in NT$ thousand) Jan.~Aug. 2018 Jan.~Aug. 2019 Sales Distribution Sales Distribution Domestic Domestic Export DomesticExport Export 229,152 54,758 160,740 46,052 19% 22% 78% 81% 14
Slide 15: Growth of National Market Distribution
Growth of National Market Distribution 100,000 Period: Jan.~Aug. of 7% indicated year 90,000 (in NT$ thousand) 80,000 70,000 60,000 19% 181% 50,000 2018 01~08 40,000 2019 01~08 74% 14% 30,000 152% 20,000 10,000 0 日本 Japan 巴基斯坦 Philippines Pakistan 菲律賓 台灣 Taiwan 美國 US 其他 Others 15
Slide 16: Sales Distribution by product category
Sales Distribution Period: Jan.~Aug. by product category of indicated year 2019年01-08 Jan.~Aug. 2019 44% 6% 30% 20% 2018年01-08 Jan.~Aug. 2018 43% 9% 38% 10% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 止痛類 Analgesic 皮膚抗菌類 Antifungal 賦型劑 Excipient 其他 Others 16
Slide 17: Growth of Sales Volumes
Growth of Sales Volumes Period: Jan.~Aug. of indicated year (in NT$ thousand) 40% 100,000 6% 80,000 60,000 122% 40,000 -11% 1,247% 202% 20,000 0 止痛類 Analgesic 皮膚抗菌類 Antifungal 賦型劑 Excipient 降血壓藥類 Antihypertensive 代工 CMO 抗皰疹病毒類 Anti-HSV 2018 2019 17
Slide 18: Market Changes and Trends
Market Changes and Trends Due to environmental policy shifts in China, API and intermediate manufacturers have been forced to relocate, close or halt production, creating supply chain disruptions. Production limits are in effect from Oct. to Mar. each year in China (expected to become routine for ne
Slide 19: New Product Development Strategy
New Product Development Strategy DMF of new products and DMF Developme registrations mainly in high-price market nt of new such as Japan, US, Canada, Europe; partially products in Australia, China, Southeast and Africa. Cost Reductions, Continuing Improvement of Existing Competitiven Processes; Deve
Slide 20: 2019 New Product Development Plan
2019 New Product Development Plan Market of Market of Market of Product Indication Area Area (FDF) World (FDF) World (amount) % Change (USD) (USD) Consumption in kg Short-term RVB Anticoagulant JP/US 5265.7M 9406.4M 39,168 17.7% TOP Hyponatremia JP/US 200M 800M 791 35.4% PLC Local anesthetic JP 30M
Slide 21: Thank You for Your Attention!
YOU CAN TRUST FOREVER Thank You for Your Attention! 21
Slide 22: YUNG ZIP CHEMICAL
® YUNG ZIP CHEMICAL
Yung Zip Chemical Ind. — Investors Relations Conference 2019 on 6ix